Date of event
-
Continuing Education Credits
CME
ABIM MOC
Add to Calendar 2021-06-17 10:00:00 2022-06-30 23:59:00 Emerging Topic Conference - Current Challenges in Clinical Management and Drug Development in NASH AASLD alonzo.tolver@boldrstrategy.com America/New_York public

UPDATE — The OnDemand 2021 AASLD Emerging Topic Conference was released on June 28, 2021 and is available FOR PURCHASE in AASLD’s educational portal, LiverLearning® until June 30, 2022. Register for / view the OnDemand Course


 

Course Description / Needs Statement

The conference, Current Challenges in Clinical Management and Drug Development in NASH has been designed to bring together liver scientists (translational researchers and clinical investigators) with strong expertise in fatty liver disease. The goals of this symposium are to: i) allow both communities to learn about each other’s progresses, ii) review the most recent preclinical and clinical investigations in their respective field and, iii) promote the rapid emergence of novel and efficient therapeutic options.

Program Chairs

  • Rohit Loomba, MD
  • Stephen A. Harrison, MD, FAASLD

Conference Format

The online live-streaming conference will have pre-recorded presentations for viewing along with live elements such as panel discussions, a poster session, and the opportunity to get your faculty questions answered in real time with both Chat and Q&A features available throughout the event.

Continuing Education

  • Continuing Medical Education (CME): 9.50 AMA PRA Category 1 Credits™
  • Maintenance of Certification: 9.50 ABIM MOC Points

Current Challenges in Clinical Management and Drug Development in NASH is supported by an unrestricted educational grant provided by Novo Nordisk

Needs Statement

The conference has been designed to bring together liver scientists (translational researchers and clinical investigators) with strong expertise in fatty liver disease. The goals of this symposium are to: i) allow both communities to learn about each other’s progresses, ii) review the most recent preclinical and clinical investigations in their respective field and, iii) promote the rapid emergence of novel and efficient therapeutic options.
 

Learning Objectives

Upon completion of this activity, learners will be able to:

  • Increases understanding of non-alcoholic steatohepatitis (NASH) to be more efficient in identifying current or future management strategies for patients.
  • Enhanced knowledge and understanding of NASH to be informed of the most recent basic discoveries in the field.
  • Learners will improve their knowledge and understanding of NASH.

Target Audience

  • Gastroenterologists      
  • Nurses
  • Pharmacists
  • Physician Assistants     
  • Surgeons         
  • Fellows/Trainees
  • Basic Scientists
  • Graduate Students
  • Post-docs
  • Patients Association     

Credits Offered

Continuing Medical Education (CME): 9.50 AMA PRA Category 1 Credits

ABIM Maintenance of Certification (MOC): 9.50 ABIM MOC Points
 

Accreditation and Designation Statements

Continuing Medical Education (CME) 
The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this live activity for a maximum of 9.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

American Board of Internal Medicine Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 9.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.  Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.  It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.


LIVE EVENT AND ONDEMAND: Claiming CME Credits and ABIM MOC Points

CME Credits

Physicians and other health care professionals seeking AMA PRA Category 1 CreditsTM from the live event (held on June 17 – 18, 2021) continuing medical education activity must complete an evaluation by Thursday, July 15, 2021. If purchasing the OnDemand conference product the CME evaluation must be completed by June 30, 2022.

The CME evaluation can be found in the conference platform at the bottom of the Agenda section.  Please watch all presentations before completing the evaluation.

 

MOC Points

Physicians seeking ABIM MOC points for the live event (held on June 17 – 18, 2021) must complete the CME and MOC evaluation by Thursday, July 15, 2021.  Requests for MOC after this date will not be honored. The MOC evaluation is included in the CME evaluation.

MOC Points will be reported to the ABIM for the live event by the end of July 2021 for attendees who successfully complete the MOC evaluation.  For the OnDemand activity, MOC points will be reported 30 days after the participant submits the MOC evaluation.

Session I: Current Management of NASH
Moderators: Raymond T. Chung, MD, FAASLD and Suzanne R. Sharpton, MD, MAS

  • 10:00 am – 10:10 am ET
    Welcome and Opening Remarks
    Rohit Loomba, MD
  • 10:10 am – 10:30 am ET
    Epidemiology and Natural History of NASH
    Zobair M. Younossi, MD, MPH, FAASLD
  • 10:30 am – 10:50 am ET
    Pathogenesis of NASH
    Brent A. Tetri, MD, FAASLD
  • 10:50 am – 11:10 am ET
    Liver Histologic Assessment and Differential Diagnosis in NAFLD
    David Kleiner, MD, PhD
  • 11:10 am – 11:30 am ET
    Lifestyle, Current Pharamacologic Treatment of NASH and Bariatric Surgery
    Kathleen E. Corey, MD, MPH, MMSc
  • 11:30 am – 11:50 am ET
    Panel Discussion
  • 11:50 am – 1:00 pm ET
    Lunch and Networking Opportunities

    Optional Breakout Recordings (15 minute recordings available OnDemand throughout the conference)

    Differential Diagnosis of Elevated ALT: What Labs to Order and  How to Diagnose NASH in Clinic?
    Lisa M. Richards, MSN, FNP, AF-AASLD

    How to Take History, Physical, Alcohol and NIT Assessment in Clinic?
    Summer Collier, MSN, FNP-BC, AAHIVS

    Diet and Exercise Counseling for NASH Patients
    Monica A. Tincopa, MD MSc

 

Session II: NASH Progression and Co-morbidities
Moderators: Rohit Loomba, MD and NAIM ALkhouri, md

  • 1:00 pm – 1:20 pm ET
    Diagnosis and Management of Pediatric NASH
    Marialena Mouzaki, MD
  • 1:20 pm – 1:40 pm ET
    How to Use NIT in Risk Stratification in Clinical Care?
    Naim Alkhouri, MD
  • 1:40 pm – 2:00 pm ET
    NASH Related HCC and Liver Transplantation
    Veeral H. Ajmera, MD
  • 2:00 pm – 2:05 pm ET
    Oral Abstract Presentation #1
  • 2:05 pm – 2:10 pm ET
    Oral Abstract Presentation #2
  • 2:10 pm – 2:20 pm ET
    Impact of COVID-19 on Clinical Trial Design and Participation
    Elizabeth C. Verna, MD, MS
  • 2:20 pm – 2:40 pm ET
    Panel Discussion
  • 2:40 pm – 3:00 pm ET
    Break

Session III: NASH Trials- All things Considered
Moderators: Naim Alkhouri, MD and Summer Collier, MSN, FNP-BC

  • 3:00 pm – 3:10 pm ET
    Ideal NASH Drug
    Brent A. Tetri, MD, FAASLD
  • 3:10 pm – 3:30 pm ET
    NASH Related Fibrosis and Cirrhosis: Phase 2/3/4 Endpoints
    Arun J. Sanyal, MD, FAASLD
  • 3:30 pm – 3:50 pm ET
    Patient Selection and Screen Fail Rate Mitigation (NASH and Cirrhosis)
    Stephen A. Harrison, MD, FAASLD
  • 3:50 pm – 3:55 pm ET
    Oral Abstract Presentation #3
  • 3:55 pm – 4:00 pm ET
    Oral Abstract Presentation #4
  • 4:00 pm – 4:20 pm ET
    Stabilization of Placebo Response Rates in NASH and Cirrhosis Trials
    Mary E. McCarthy Rinella, MD, FAASLD
  • 4:20 pm – 4:45 pm ET
    Panel Discussion
  • 4:45 pm ET
    End of Day One

Session IV: Endpoint Analysis
Moderators: Veeral H. Ajmera, MD and Michelle Long, MD, MSc

  • 10:00 am – 10:10 am ET
    Opening Remarks
    Stephen A. Harrison, MD, FAASLD
  • 10:10 am – 10:30 am ET
    Refining Histopathologic Data Collection and Analysis
    Cynthia A. Behling, MD, PhD
  • 10:30 am – 10:50 am ET
    Utilization of AI in Pathology in Clinical Trials in NASH and Cirrhosis
    Mazen Noureddin, MD
  • 10:50 am – 11:10 am ET
    Combination Therapy and What Does the Future Look Like
    Michael R. Charlton, MD, FRCP
  • 11:10 am – 11:45 am ET
    Panel Discussion
  • 11:45 am – 1:00 pm ET
    Lunch

Session V: Assessment of Response and Competing Risks
Moderators: Anna Mae Diehl, MD, FAASLD and Stephen A. Harrison, MD, FAASLD

  • 1:00 pm – 1:20 pm ET
    Emerging Therapies for NASH Cirrhosis
    Manal F. Abdelmalek, MD, MPH, FAASLD
  • 1:20 pm – 1:40 pm ET
    Liver Histology, Functional and HVPG in NASH Cirrhosis
    Vincent Wong, MD
  • 1:40 pm – 2:00 pm ET
    Non-invasive Biomarkers for Treatment Response
    Rohit Loomba, MD
  • 2:00 pm – 2:20 pm ET
    Competing Risks of DILI, Gall Bladder Disease, and Decompensation in Cirrhosis Trials and Their Impact on Trial Design
    Naga P. Chalasani, MD, FAASLD
  • 2:20 pm – 2:40 pm ET
    Panel Discussion
  • 2:40 pm – 3:00 pm ET
    Break

Session VI: Deep-dive Innovations in Design
Moderators: Rohit Loomba, MD and Mary E. McCarthy Rinella, MD, FAASLD

  • 3:00 pm – 3:20 pm ET
    Clinical Endpoints, Sample-size for Phase 2b and Phase 3 Trials in NASH Cirrhosis
    Juan G. Abraldes, MD
  • 3:20 pm – 3:40 pm ET
    Genetic (PNPLA3, TM6SF2 and HSD17B13) Targetting of Therapies of NASH and Cirrhosis
    Quentin M. Anstee, MBBS, PhD, FRCP
  • 3:40 pm – 4:00 pm ET
    Break
  • 4:00 pm – 4:20 pm ET
    Adaptive Trial Designs for Combined Phase 2b/3 and Parallel Trial Design in NASH and Cirrhosis
    Frank A. Anania, MD, FAASLD, FACP, AGAF
  • 4:20 pm – 4:40 pm ET
    Panel Discussion
  • 4:40 pm – 5:00 pm ET
    Wrap-up
    Stephen A. Harrison, MD, FAASLD
  • 5:00 pm ET
    Conference Adjourned

OnDemand Product Registration Pricing:

  • Member — $240
  • Trainee & Assoc. Members — $140
  • Student Member — $70
  • Non-Member — $340
    Any physician, scientist, or researcher with doctoral-level training who is not employed by Industry (pharma/device/etc.)
  • Trainee & Assoc. Non-Member — $220
    Any physician, scientist or researcher in a training program as certified by the director of their training program. This category also includes, but is not limited to, the degrees of MS, NP, PA, RN, and other related or comparable degree
  • Student Non-Member — $110
  •  Industry — $670
    Any Industry (pharma/device/etc.) employee with or without medical training
  • Patient Advocate — Complimentary
    Individuals who play a critical role in helping people, and their caregivers, with liver disease. This includes those who are employed by or volunteer for a nationally or internationally recognized tax-exempt, not-for-profit organization dedicated to advocacy for patients with liver disease; individuals who are actively engaged in the hepatology community and serving as patient representatives at public and/or private institutions that involve a network of researchers, physicians, and healthcare professionals; and those who are working on behalf of a recognized local or state organization, functioning in roles such as advocacy, community outreach, patient education, patient support, fundraising, navigation, and public policy education. (Please note: This category and corresponding complimentary registration is reserved exclusively for patient advocates and is not intended for medical/health care professionals)
  • Patients and Caregivers — Complimentary
    (Please note: This category and corresponding complimentary registration is reserved exclusively for patients and caregivers and is not intended for medical/health care professionals)